CA2537314A1 - Method of replenishing cells damaged by treatment for cancer - Google Patents
Method of replenishing cells damaged by treatment for cancer Download PDFInfo
- Publication number
- CA2537314A1 CA2537314A1 CA002537314A CA2537314A CA2537314A1 CA 2537314 A1 CA2537314 A1 CA 2537314A1 CA 002537314 A CA002537314 A CA 002537314A CA 2537314 A CA2537314 A CA 2537314A CA 2537314 A1 CA2537314 A1 CA 2537314A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cancer
- treatment
- cell
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 34
- 201000011510 cancer Diseases 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 53
- 210000000601 blood cell Anatomy 0.000 claims abstract description 15
- 241000288906 Primates Species 0.000 claims abstract description 13
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 9
- 230000003247 decreasing effect Effects 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 4
- 231100000331 toxic Toxicity 0.000 claims abstract description 4
- 230000002588 toxic effect Effects 0.000 claims abstract description 4
- 238000002512 chemotherapy Methods 0.000 claims description 16
- 230000005855 radiation Effects 0.000 claims description 5
- 238000010322 bone marrow transplantation Methods 0.000 claims description 3
- 206010016256 fatigue Diseases 0.000 description 13
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 7
- 230000001332 colony forming effect Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 3
- 108010074604 Epoetin Alfa Proteins 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 229960003388 epoetin alfa Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed herein is a method of replenishing cells damaged by treatment for cancer. The method comprises removing blood cells from a primate mammal, controllably expanding the cells at a rate which produces an expansion factor of at least 700% within 7 days while maintaining their three-dimensional geometry and their cell-to-cell support and cell-to-cell geometry, removing any toxic materials from the blood cells, and reintroducing the cells into the primate mammal within a time period sufficient to prevent the primate mammal from suffering decreased mobility due to loss of hematopoietic or other cells.
Description
METHOD OF REPLENISHING CELLS DAMAGED BY TREATMENT FOR
CANCER
Background of the Invention The present invention relates to a method of replenishing cells damaged by treatment for cancer.
One of the worse side effects of the use of chemotherapy in the treatment for cancer is the loss of energy by the patient due to loss of red blood cells.
In. the process of destroying cancer cells, chemotherapy often causes damage to other rapidly dividing cells, such as the bone marrow cells.,.Bone~.marrow is responsible for producing red blood cells, white blood cells, and platelets. The reduced activity ofthe bone marrow is named myelosuppression. Chemotherapy and radiation can depress the number of red blood cells to a low level and eventually produce tiredness, lack of energy, and anemia.
Myelosuppression is the dose-limiting toxicity of most highly effective chemotherapeutic agents. In recent yeaxs this limitation has been overcome through the use of SC
transplantation (SCT). Tn fact, SCT performed alter high-dose chemotherapy allows further escalation of dose intensity, thus increasing survival in many patients with advanced malignant diseases. Nevertheless, most patients treated with SCT
experience prolonged neutxopenia and thrombacytopenia resulting in increased morbidity and, mortality.
Labeled by some as cancer's number one side effect, fatigue is part of the illness of 72% to 95% of patients with cancer. Chronic or acute--some describe it as "hitting a wall"--the fatigue experienced by patients with cancer differs from that of healthy people.
It is debilitating and depressing, it interferes with normal activities, and it is a barrier to a person's enjoyment of life. The National Cancer Institute describes fatigue's social implications as potentially "profound,"
Fatigue, long discounted, has become more prominent because therapies have become more.aggressive and exacerbated it and because health professionals have acknowledged it as a dose-limiting toxicity of therapy and as a quantifiable and treatable side effect. It is emerging a~ a serious topic of research, which encompasses biochemical, pathophysiologic, psychologic, and behavioral variables. Unfortunately, while medical science has been making steady progress in treating cancer itself, cancer related fatigue is frequently over-looked, under-recognized and under-treated. Aside from the discomfort of feeling exhausted, fatigue can pose a number of obstacles to coping with cancer and reaping the full benefits of available treatments. Fatigue can significantly interfere with a patient's quality of life and may limit the number of chemotherapy cycles that could be administered, which may limit the effectiveness of treatment altogether.
In the past, the preferred treatment for fatigue associated with cancer treatment has been the administration of medication such as epoetin alfa'(Procrit), or when the condition becomes severe, a transfusion of red blood cells.
None of the currently available medications, such as epoetin alfa, provide full relief from fatigue due to chemotherapy. While they assist in reducing some of the problems and providing some relief, the medications also have side effects, which create a new series of problems for the patient. Likewise, a transfusion of red blood cells is generally administered only after the patient has suffered the worst effects of the fatigue.
It can therefore be seen that a need exists to minimize the fatigue associated with chemotherapy or radiation for cancer in order to provide a better quality of life for patients undergoing treatment for cancer.
Summary bf the Invention The present invention is a method of replenishing cells damaged by treatment fox cancer comprising removing blood cells from a primate mammal, controllably expanding the cells a rate which produces an expansion factor of at least seven times within 7 days while ~ai~l~g:;tl;~~~rai?xe.~ di~eu~iQna~ g~Q~etry: ~:nd their ~eXl-to-cell support,and .: .
~~llr~or~~~~l~,geo~.et~y;.~;emoting;a~y~to~iG;~at~rial~:fromthebloodcells,.and, .. ~ , rei~tx.-.a,~.~cing~the cells intoahe primate~.mammal within a time period sufficient to prevent the primate mammal from suffering decreased mobility due to loss of hematopoietic or other cells. The damage by treatment for cancer can be from bone marrow transplantation,. chemotherapy, or radiati~n.:Preferably, the reintroduction of the cells is within a:rather.short period of time,.preferably within one week after the cancer treatment proced~.re, but should be no later than within one month after the cancer treatment proceci~e., Tn_tl~e,pxeserit,i~ve,~~ion, ahe ;nt~mbpr.;of :colony forming units (CELT) granulocyte-macrop~age,.(C~U'-GM) and; of; CFU-granulocyte-macrophage-erytbroid-megakaryocyte (CFU-GEC will increase.about 7-fold and about 9-fold, respectively, by day 7 and the .. .
number of burst-forming unfits-erythroid (BFU-E) will increase about 2.7 fold by day 5 of, culture. . Significant , increases . in the numbers of .cells expressing CD34+, CD34+~CD38+,: CD3.4+lCD~3-~-.,, .CD3,.4+/,CD15+, and CD34+lCD9~+ and significant declines in the numbers of cells expressing CD34+/CD38- and CD19 surface antigens will occur.
Recombinant hematopoietic growth factors have provided the clinician with a useful tool for treating patients with chemotherapy induced myelosupp~ession.
These factors. include myeloid growth factors .such as granulocyte colony stimulating factor (G
CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) which decrease the duration of neutropenia and. the inoidence of serious infections.
' It~'is~an object of'this~invention to provide a method for replenishing cells damaged by treatment fox cancer. ~ ..
It is a further object of this invention to provide a method for reducing fatigue in patients being treated for cancer with chemotherapy or radiation.
These and still other objects and advantages of the present invention will be appaxent from the description of the preferred embodiments that follow.
Detailed Description of the Invention fihis invention may be more fully described by the preferred embodiment as' hereinafter described.
Tn the preferred embod3ment~ of this invention, hematopoietic blood cells are removed from a cancer patient prior to chemotherapy treatment. The blood cells are what are currently referred to as pluripotent adult stem cells. The blood cells are placed in a bioreactor, such as that described is United States Patent 5,702,941 which is incorporated herein by reference. The bioreactor vessel is rotated at a speed that provides for suspension of the blood cells to maintain their three-dimensional geometry and their cell-to-cell support and geometry. During the time that the cells are in the reactor, they are fed nutrients and toxic materials are removed. The cells are expanded to a volume substantially greater than the original cells. The patient is then administered chemotherapy.
In still another embodiment of this invention, peripheral blood (PB) cells are obtained from normal stem cell (SC) donors. In brief, mononuclear cells (MrTCs) are obtained from the first apheresis product collected from SC donors. Prior to apheresis, each donor is treated with G-CSF 6 ~: g/kg every 12 hr over 3 days and then once on day 4.
MNCs are collected by subjecting each donoe's total blood volume to 3 rounds of continuous-flow leukapheresis through a Cobe Spectra cell separator.
Operative Method A) Collection and maintenace of cells Collected MNCs (0.75 x 106 cells/ml) are suspended in Iscove's modified Dulbecco's medium (llVIDM) (GIBCO, Grand Island, hIY) supplemented with 20°t° either fetal calf serum (FCS) (Flow Laboratories, McClean, VA), 5% human albumin (HA) or 20% human plasma, 100 nglml recombinant human G-CSF (Amgen Inc., Thousand Oaks, CA), and 100 ng/ml recombinant human stem cell factor (SCF) (Amgen). The culture mix is injected into 300 mI or 500 ml Life Cell nonpyrogenic plastic bags (Baxter, Deerfield, IL) and placed in a humidified incubator at 37EC under an atmosphere of 5%
C02. The culture bags are inspected daily. On days 2, 5, 6, and 7, each culture is mixed, and a sample is aspirated, counted using the trypan-blue exclusion test. If the concentration of cells in a bag exceeds 0.75 x 106 cells/ml, then llVIDM
supplemented with either 20% FCS, 5% HA. or 20% human plasma, 100 ng/ml G-CSF, and 100 ug/ml SCF is injected into the bag to adjust the cellular concentration to 0.75'x 106 cells/m1.
s B) Analysis of hematopoietic colony-forming cells Hematopoietic colony forrr~ing cells are assayed using a modification of a previously described assay In brief, 105 MNCs are cultured in 0.8%
methylcellulose with 1MDM, 30% FCS, 1.0 U/ml erythropoietin (Amgen), 50 ng/ml recombinant human GM-CSF (Zinmunex Corp., Seattle, WA), and SO ng/ml SCF (Amgen). One-noilliliter aliquots of each culture mixture are then placed in 35-mm Petri dishes (Nunc Inc., Naperville, IL) and incubated in duplicate at 37EC in air in a humidified atmosphere of 5% CO~. All cultures are evaluated after 7 days for the number of burst forming unit-erythroid ($FET: E). ,colonies x (defined east aggre. gates of more than 500 hemoglobinized cells o~ 3 or more erythroid subcolonies); for the number of colony forming units grariulocyte-macrophage (CFU-GM) colonies of granulocytic or monocyte-macrophage cells 'or both, and for the number of CFU-granulocyte-erythroid-macrophage-megakaryocyte (CFLT-GEM1VI) containing all elements. Individual colonies are plucked from the cultures with a micropipette and analyzed far cellular composition.
C) Analysis of lymphocytes Lymphocytes are analyzed by 2-color staining using the following antibody combinations:. CD56+C.D.l,f;PE/.CD3-F~3C;:3:~~3-PE/CD4-FTTC, CD3-PE/CD8-FITC, CD19-PE. Controls include ;TgG1-PE/IgG1-FITC for isotype. and CD14-PE/CD45-FITC
for gatialg. Progenitor cells are analyzed by 3-color staining with the fluorochromes PerCPIFE/FITC using the : following antibody combinations: CD45/CD90/CD34, CD451~D34/CD38, CD45/CD34/CD33, and CD45/CD34/CD15. CD45/IgG1/IgGl is used as a control. In brief, 106 cells from each donor are incubated with 10 :1 of antibodies at 2-8EC for 15 minutes in the dark and then washed twice in phosphate-buffered saline. Then the cells are resuspended, fixed with 1% formaldehyde, and analyzed on a FACScan flow cytometer (Becton-Dickinson) equipped with ~
CELLQuest .
software (Becton Dickinson). For analyses of lymphocytes, 10,000 cells are acquired from each tube, and then gated on the basis of the forward and right angle light scatter patterns. The cutoff point is visually set at a level above background positivity exhibited by isotype controls. For analyses of progenitor cells, 75,000 cells .from each tube is acquired and then sequentially gated.
D) increase in hermatopietic colony-forming cells Incubation of the donors' PB cells in my tissue culture system significantly increases the numbers of hematopoietic colony forming cells. A constant increase in the numbers of CFU-GM (up to 7-fold) and CFU-GEMM (up to 9-fold) colony forming cells is obsezved up to day 7 with no clear plateau.
E) Increase in CD34+ cells Incubation of MNCs from normal donors in my tissue culture system significantly increases the numbers of CD34+ cells. The average number of CD34+ cells increased 10-fold by day 6 of culture and plateaus on that same day. The relative number of CD34+ cells co-expressing the myeloid-lineage markers CD15 and CD33 increases significantly by days S and 6.
Within one week of the chemotherapy treatment, the expanded cells are reintroduced into the body thereby allowing the body to maintain a sufficient level of replenished cells ~to overcome the fatigue caused by the chemotherapy Even though the preferred embodiment of this invention is described above, it will be appreciated by those skilled in the art that other modifications can be made within the scope of this invention.
CANCER
Background of the Invention The present invention relates to a method of replenishing cells damaged by treatment for cancer.
One of the worse side effects of the use of chemotherapy in the treatment for cancer is the loss of energy by the patient due to loss of red blood cells.
In. the process of destroying cancer cells, chemotherapy often causes damage to other rapidly dividing cells, such as the bone marrow cells.,.Bone~.marrow is responsible for producing red blood cells, white blood cells, and platelets. The reduced activity ofthe bone marrow is named myelosuppression. Chemotherapy and radiation can depress the number of red blood cells to a low level and eventually produce tiredness, lack of energy, and anemia.
Myelosuppression is the dose-limiting toxicity of most highly effective chemotherapeutic agents. In recent yeaxs this limitation has been overcome through the use of SC
transplantation (SCT). Tn fact, SCT performed alter high-dose chemotherapy allows further escalation of dose intensity, thus increasing survival in many patients with advanced malignant diseases. Nevertheless, most patients treated with SCT
experience prolonged neutxopenia and thrombacytopenia resulting in increased morbidity and, mortality.
Labeled by some as cancer's number one side effect, fatigue is part of the illness of 72% to 95% of patients with cancer. Chronic or acute--some describe it as "hitting a wall"--the fatigue experienced by patients with cancer differs from that of healthy people.
It is debilitating and depressing, it interferes with normal activities, and it is a barrier to a person's enjoyment of life. The National Cancer Institute describes fatigue's social implications as potentially "profound,"
Fatigue, long discounted, has become more prominent because therapies have become more.aggressive and exacerbated it and because health professionals have acknowledged it as a dose-limiting toxicity of therapy and as a quantifiable and treatable side effect. It is emerging a~ a serious topic of research, which encompasses biochemical, pathophysiologic, psychologic, and behavioral variables. Unfortunately, while medical science has been making steady progress in treating cancer itself, cancer related fatigue is frequently over-looked, under-recognized and under-treated. Aside from the discomfort of feeling exhausted, fatigue can pose a number of obstacles to coping with cancer and reaping the full benefits of available treatments. Fatigue can significantly interfere with a patient's quality of life and may limit the number of chemotherapy cycles that could be administered, which may limit the effectiveness of treatment altogether.
In the past, the preferred treatment for fatigue associated with cancer treatment has been the administration of medication such as epoetin alfa'(Procrit), or when the condition becomes severe, a transfusion of red blood cells.
None of the currently available medications, such as epoetin alfa, provide full relief from fatigue due to chemotherapy. While they assist in reducing some of the problems and providing some relief, the medications also have side effects, which create a new series of problems for the patient. Likewise, a transfusion of red blood cells is generally administered only after the patient has suffered the worst effects of the fatigue.
It can therefore be seen that a need exists to minimize the fatigue associated with chemotherapy or radiation for cancer in order to provide a better quality of life for patients undergoing treatment for cancer.
Summary bf the Invention The present invention is a method of replenishing cells damaged by treatment fox cancer comprising removing blood cells from a primate mammal, controllably expanding the cells a rate which produces an expansion factor of at least seven times within 7 days while ~ai~l~g:;tl;~~~rai?xe.~ di~eu~iQna~ g~Q~etry: ~:nd their ~eXl-to-cell support,and .: .
~~llr~or~~~~l~,geo~.et~y;.~;emoting;a~y~to~iG;~at~rial~:fromthebloodcells,.and, .. ~ , rei~tx.-.a,~.~cing~the cells intoahe primate~.mammal within a time period sufficient to prevent the primate mammal from suffering decreased mobility due to loss of hematopoietic or other cells. The damage by treatment for cancer can be from bone marrow transplantation,. chemotherapy, or radiati~n.:Preferably, the reintroduction of the cells is within a:rather.short period of time,.preferably within one week after the cancer treatment proced~.re, but should be no later than within one month after the cancer treatment proceci~e., Tn_tl~e,pxeserit,i~ve,~~ion, ahe ;nt~mbpr.;of :colony forming units (CELT) granulocyte-macrop~age,.(C~U'-GM) and; of; CFU-granulocyte-macrophage-erytbroid-megakaryocyte (CFU-GEC will increase.about 7-fold and about 9-fold, respectively, by day 7 and the .. .
number of burst-forming unfits-erythroid (BFU-E) will increase about 2.7 fold by day 5 of, culture. . Significant , increases . in the numbers of .cells expressing CD34+, CD34+~CD38+,: CD3.4+lCD~3-~-.,, .CD3,.4+/,CD15+, and CD34+lCD9~+ and significant declines in the numbers of cells expressing CD34+/CD38- and CD19 surface antigens will occur.
Recombinant hematopoietic growth factors have provided the clinician with a useful tool for treating patients with chemotherapy induced myelosupp~ession.
These factors. include myeloid growth factors .such as granulocyte colony stimulating factor (G
CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) which decrease the duration of neutropenia and. the inoidence of serious infections.
' It~'is~an object of'this~invention to provide a method for replenishing cells damaged by treatment fox cancer. ~ ..
It is a further object of this invention to provide a method for reducing fatigue in patients being treated for cancer with chemotherapy or radiation.
These and still other objects and advantages of the present invention will be appaxent from the description of the preferred embodiments that follow.
Detailed Description of the Invention fihis invention may be more fully described by the preferred embodiment as' hereinafter described.
Tn the preferred embod3ment~ of this invention, hematopoietic blood cells are removed from a cancer patient prior to chemotherapy treatment. The blood cells are what are currently referred to as pluripotent adult stem cells. The blood cells are placed in a bioreactor, such as that described is United States Patent 5,702,941 which is incorporated herein by reference. The bioreactor vessel is rotated at a speed that provides for suspension of the blood cells to maintain their three-dimensional geometry and their cell-to-cell support and geometry. During the time that the cells are in the reactor, they are fed nutrients and toxic materials are removed. The cells are expanded to a volume substantially greater than the original cells. The patient is then administered chemotherapy.
In still another embodiment of this invention, peripheral blood (PB) cells are obtained from normal stem cell (SC) donors. In brief, mononuclear cells (MrTCs) are obtained from the first apheresis product collected from SC donors. Prior to apheresis, each donor is treated with G-CSF 6 ~: g/kg every 12 hr over 3 days and then once on day 4.
MNCs are collected by subjecting each donoe's total blood volume to 3 rounds of continuous-flow leukapheresis through a Cobe Spectra cell separator.
Operative Method A) Collection and maintenace of cells Collected MNCs (0.75 x 106 cells/ml) are suspended in Iscove's modified Dulbecco's medium (llVIDM) (GIBCO, Grand Island, hIY) supplemented with 20°t° either fetal calf serum (FCS) (Flow Laboratories, McClean, VA), 5% human albumin (HA) or 20% human plasma, 100 nglml recombinant human G-CSF (Amgen Inc., Thousand Oaks, CA), and 100 ng/ml recombinant human stem cell factor (SCF) (Amgen). The culture mix is injected into 300 mI or 500 ml Life Cell nonpyrogenic plastic bags (Baxter, Deerfield, IL) and placed in a humidified incubator at 37EC under an atmosphere of 5%
C02. The culture bags are inspected daily. On days 2, 5, 6, and 7, each culture is mixed, and a sample is aspirated, counted using the trypan-blue exclusion test. If the concentration of cells in a bag exceeds 0.75 x 106 cells/ml, then llVIDM
supplemented with either 20% FCS, 5% HA. or 20% human plasma, 100 ng/ml G-CSF, and 100 ug/ml SCF is injected into the bag to adjust the cellular concentration to 0.75'x 106 cells/m1.
s B) Analysis of hematopoietic colony-forming cells Hematopoietic colony forrr~ing cells are assayed using a modification of a previously described assay In brief, 105 MNCs are cultured in 0.8%
methylcellulose with 1MDM, 30% FCS, 1.0 U/ml erythropoietin (Amgen), 50 ng/ml recombinant human GM-CSF (Zinmunex Corp., Seattle, WA), and SO ng/ml SCF (Amgen). One-noilliliter aliquots of each culture mixture are then placed in 35-mm Petri dishes (Nunc Inc., Naperville, IL) and incubated in duplicate at 37EC in air in a humidified atmosphere of 5% CO~. All cultures are evaluated after 7 days for the number of burst forming unit-erythroid ($FET: E). ,colonies x (defined east aggre. gates of more than 500 hemoglobinized cells o~ 3 or more erythroid subcolonies); for the number of colony forming units grariulocyte-macrophage (CFU-GM) colonies of granulocytic or monocyte-macrophage cells 'or both, and for the number of CFU-granulocyte-erythroid-macrophage-megakaryocyte (CFLT-GEM1VI) containing all elements. Individual colonies are plucked from the cultures with a micropipette and analyzed far cellular composition.
C) Analysis of lymphocytes Lymphocytes are analyzed by 2-color staining using the following antibody combinations:. CD56+C.D.l,f;PE/.CD3-F~3C;:3:~~3-PE/CD4-FTTC, CD3-PE/CD8-FITC, CD19-PE. Controls include ;TgG1-PE/IgG1-FITC for isotype. and CD14-PE/CD45-FITC
for gatialg. Progenitor cells are analyzed by 3-color staining with the fluorochromes PerCPIFE/FITC using the : following antibody combinations: CD45/CD90/CD34, CD451~D34/CD38, CD45/CD34/CD33, and CD45/CD34/CD15. CD45/IgG1/IgGl is used as a control. In brief, 106 cells from each donor are incubated with 10 :1 of antibodies at 2-8EC for 15 minutes in the dark and then washed twice in phosphate-buffered saline. Then the cells are resuspended, fixed with 1% formaldehyde, and analyzed on a FACScan flow cytometer (Becton-Dickinson) equipped with ~
CELLQuest .
software (Becton Dickinson). For analyses of lymphocytes, 10,000 cells are acquired from each tube, and then gated on the basis of the forward and right angle light scatter patterns. The cutoff point is visually set at a level above background positivity exhibited by isotype controls. For analyses of progenitor cells, 75,000 cells .from each tube is acquired and then sequentially gated.
D) increase in hermatopietic colony-forming cells Incubation of the donors' PB cells in my tissue culture system significantly increases the numbers of hematopoietic colony forming cells. A constant increase in the numbers of CFU-GM (up to 7-fold) and CFU-GEMM (up to 9-fold) colony forming cells is obsezved up to day 7 with no clear plateau.
E) Increase in CD34+ cells Incubation of MNCs from normal donors in my tissue culture system significantly increases the numbers of CD34+ cells. The average number of CD34+ cells increased 10-fold by day 6 of culture and plateaus on that same day. The relative number of CD34+ cells co-expressing the myeloid-lineage markers CD15 and CD33 increases significantly by days S and 6.
Within one week of the chemotherapy treatment, the expanded cells are reintroduced into the body thereby allowing the body to maintain a sufficient level of replenished cells ~to overcome the fatigue caused by the chemotherapy Even though the preferred embodiment of this invention is described above, it will be appreciated by those skilled in the art that other modifications can be made within the scope of this invention.
Claims (13)
1. A method of replenishing cells damaged by treatment for cancer comprising removing blood cells from a primate mammal, controllably expanding the cells a rate which produces an expansion factor of at least seven times within 7 days while maintaining their three-dimensional geometry and their cell-to-cell support and cell-to-cell geometry, removing any toxic materials from the blood cells, and reintroducing the cells into the primate mammal within a time period sufficient to prevent the primate mammal from suffering decreased mobility due to loss of hematopoietic or other cells.
2. A method as in Claim 1 wherein the treatment for cancer is bone marrow transplantation.
3. A method as is Claim 1 wherein the treatment for cancer is chemotherapy.
4. A method as in Claim 1 wherein the treatment for cancer is radiation.
5. A method as in Claim 1 wherein the reintroduction of the expanded blood cells is accomplished within 1 month of the treatment for cancer.
6. A method as in Claim 1 wherein the reintroduction of the expanded blood cells is accomplished within 1 week of the treatment for cancer.
7. A method of replenishing cells damaged by treatment for cancer comprising removing peripheal blood cells from a primate mammal, expanding the cells while maintaining their three-dimensional geometry and their cell-to-cell support and cell-to-cell geometry, removing any toxic materials from the peripheal blood cells, and reintroducing the cells into the primate mammal within a time period sufficient to prevent the primate mammal from suffering decreased mobility due to loss of hematopoietic or other cells.
8. A method as in Claim 7 wherein the primate mammal is a human.
9. A method as in Claim 7 wherein the treatment for cancer is bone marrow transplantation.
10. A method as is Claim 7 wherein the treatment for cancer is chemotherapy.
11. A method as in Claim 7 wherein the treatment for cancer is radiation.
12. A method as in Claim 7 wherein the reintroduction of the expanded blood cells is accomplished within 1 month of the treatment for cancer.
13. A method as in Claim 7 wherein the reintroduction of the expanded blood cells is accomplished within 1 week of the treatment for cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/027248 WO2005032566A1 (en) | 2003-09-02 | 2003-09-02 | Method of replenishing cells damaged by treatment for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2537314A1 true CA2537314A1 (en) | 2005-04-14 |
Family
ID=34421164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002537314A Abandoned CA2537314A1 (en) | 2003-09-02 | 2003-09-02 | Method of replenishing cells damaged by treatment for cancer |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1660105A1 (en) |
| JP (1) | JP2007521236A (en) |
| CN (1) | CN1826125A (en) |
| BR (1) | BR0318491A (en) |
| CA (1) | CA2537314A1 (en) |
| WO (1) | WO2005032566A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI634949B (en) * | 2013-04-23 | 2018-09-11 | 獨立行政法人產業技術綜合研究所 | Method for producing catalyst for cyclic |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635387A (en) * | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5277701A (en) * | 1991-11-15 | 1994-01-11 | Regents Of The University Of Minnesota | Treatment of aluimmunization and refractoriness to platelet transfusion by protein A column therapy |
| US6436387B1 (en) * | 1992-11-24 | 2002-08-20 | G.D. Searle & Co. | Methods of ex-vivo expansion of hematopoietic cells using multivariant IL-3 hematopoiesis chimera proteins |
| DE4240635C2 (en) * | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Multiplication of hematopoietic progenitor cells ex vivo and compositions of hematopoietic growth factors |
| US5702941A (en) * | 1993-09-09 | 1997-12-30 | Synthecon, Inc. | Gas permeable bioreactor and method of use |
| US5599705A (en) * | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
-
2003
- 2003-09-02 CA CA002537314A patent/CA2537314A1/en not_active Abandoned
- 2003-09-02 CN CNA03827017XA patent/CN1826125A/en active Pending
- 2003-09-02 EP EP03818823A patent/EP1660105A1/en not_active Withdrawn
- 2003-09-02 WO PCT/US2003/027248 patent/WO2005032566A1/en active Application Filing
- 2003-09-02 BR BRPI0318491-9A patent/BR0318491A/en not_active IP Right Cessation
- 2003-09-02 JP JP2005509355A patent/JP2007521236A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1660105A1 (en) | 2006-05-31 |
| BR0318491A (en) | 2006-09-12 |
| WO2005032566A1 (en) | 2005-04-14 |
| CN1826125A (en) | 2006-08-30 |
| JP2007521236A (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sandstrom et al. | Effects of CD34+ cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells | |
| Torok-Storb et al. | Regulation of in vitro erythropoiesis by normal T cells: evidence for two T-cell subsets with opposing function | |
| Rebel et al. | Amplification of Sca-1+ Lin-WGA+ cells in serum-free cultures containing steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential | |
| Ji et al. | Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia | |
| Cesana et al. | CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF | |
| Boyum et al. | Regulation of bone marrow cell growth in diffusion chambers: The effect of adding normal and leukemic (CML) polymorphonuclear granulocytes | |
| WO1993012805A1 (en) | Methods for regulatory lineages of human hematopoietic cells | |
| US20040077985A1 (en) | Method of replenishing cells damaged by treatment for cancer | |
| Tarella et al. | Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high‐dose chemotherapy+ G‐CSF | |
| Galy et al. | Generation of T cells from cytokine-mobilized peripheral blood and adult bone marrow CD34+ cells | |
| Keever et al. | NK and LAK activities from human marrow progenitors: I. The effects of interleukin-2 and interleukin-1 | |
| US20070172466A1 (en) | Method of replenishing cells damaged by treatment for cancer | |
| US20040044300A1 (en) | Method of replenishing cells damaged by treatment for cancer | |
| CA2537314A1 (en) | Method of replenishing cells damaged by treatment for cancer | |
| Enokihara et al. | Interleukin 2 stimulates the T‐cells from patients with eosinophilia to produce CFU‐Eo growth stimulating factor | |
| US20040076620A1 (en) | Method of repairing primate mammalian tissue | |
| Ariyama et al. | Synergistic effects of stem cell factor and interleukin 6 or interleukin 11 on the expansion of murine hematopoietic progenitors in liquid suspension culture | |
| MXPA06002378A (en) | Method of replenishing cells damaged by treatment for cancer | |
| KR20060085332A (en) | Method of replenishing cells damaged by treatment for cancer | |
| Schwartz et al. | Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow | |
| Ogata et al. | Effects of interleukin 2 on myelodysplastic syndromes | |
| Estrov et al. | Ex vivo expansion of apheresis‐derived peripheral blood hematopoietic progenitors | |
| Roecklein et al. | Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood | |
| US20040043009A1 (en) | Method of repairing primate mammalian tissue | |
| US20040042997A1 (en) | Method of regenerating human tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |